News Headlines

  1. ImmuPharma Selects Thermo Fisher Scientific Drug Product CDMO For Kapiglucagon Program 7/22/2026

    ImmuPharma plc, the specialist drug discovery and development company, is pleased to announce that, following a competitive tender process, it has selected Thermo Fisher Scientific, the world leader in serving science, as its drug product (“DP”) and contract development and manufacturing organisation (“CDMO”) for its Kapiglucagon program.

  2. eXmoor Pharma And Evox Therapeutics Complete Technology Transfer Programme For Exosome-Enabled Gene Editing Technology 7/21/2026

    eXmoor Pharma (‘eXmoor’ ), the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Evox Therapeutics (‘Evox’) have completed a technology transfer programme for Evox’s exosome-enabled gene editing technology and specifically its MSH3-targeted programme for the treatment of Huntington’s disease.

  3. PolyPid Announces Exclusive Partnership With Azurity Pharmaceuticals For The Commercialization Of D-PLEX₁₀₀ In The U.S. And Canada 7/21/2026

    PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specialty pharmaceutical company, for the commercialization of D-PLEX100 in the United States and Canada for the prevention of surgical site infections (“SSIs”).

  4. Lonza And Engitix Announce License Agreement To Advance Targeted ADC Development 7/21/2026

    Lonza, the world's leading contract development and manufacturing organization (CDMO), and Engitix, a global leader in ECM-based drug discovery and development, today announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs) and deliver life-changing therapies for patients with chronic diseases.

  5. SK pharmteco And Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy Program 7/21/2026

    SK pharmteco today announced details of its ongoing strategic manufacturing partnership with Genethon, a France-based pioneering nonprofit research and development organization dedicated to gene therapy for genetic diseases.

  6. Restore Vision And Forge Biologics Announce AAV Development And cGMP Manufacturing Partnership 7/21/2026

    Restore Vision, Inc. (“Restore Vision”), a clinical-stage biotechnology company advancing gene therapies for retinal disorders, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to support RV-001, Restore Vision’s investigational GPCR-based optogenetic AAV gene therapy for patients with retinitis pigmentosa.

  7. Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T 7/21/2026

    Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”), a clinical-stage cell therapy company with extensive expertise in CD7-targeted CAR-T development and clinical translation.

  8. Pharmala Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights To ALA-002 7/21/2026

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has entered into a definitive license agreement (the “Agreement”) on July 20th, 2026 with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter”), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla’s lead drug candidate, in the United States.

  9. Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31M 7/21/2026

    Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited, a publicly listed biopharmaceutical company with more than 30 years of industry experience.

  10. MaxCyte® Announces Multi-Platform Technology License Partnership With Genentech® To Advance Cell Therapy Development 7/21/2026

    MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.